Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2002, Pages 61-65

  Crul, M ^a,b   De Klerk, G J ^a   Swart, M ^a   Weiner, L ^c   Palmer, P A ^d   Bol, C J ^d   Beijnen, J H ^b,e   Schellens, J H M ^a,e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Sioterveert Hospital   (Netherlands)

^c FOX CHASE CANCER CENTER   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer agent; Bioequivalence; R 115777; Solid tumors

Indexed keywords

TIPIFARNIB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TABLET;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUINOLONES; TABLETS;

EID: 0036209080     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190407     Document Type: Article

References (17)

1. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
2. The ras signal transduction pathway
3. Farnesyl transferase inhibitors: Current developments and future perspectives
4. Ras Genes
5. Ras and human tumors
6. Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of harvey murine sarcoma virus
7. GTPase activating proteins
8. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
9. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
10. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene transformed fibroblasts and a human colon carcinoma xenograft in nude mice
11. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems
12. Phase I and pharmacokinetic study of farnesyl proten transferase inhibitor R115777 in advanced cancer
13. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer-submitted
14. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
15. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities